GlassScriptPhysician profile
Melissa Graham
NPI 1164205415
$2,182.97
in general payments reported to CMS, 2019-2025
18 companies · $942 in 2025
The $942 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,241 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $332.59 | 2024-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $279.20 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $178.90 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $175.97 | 2024 | Lybalvi, Aristada |
| Abbvie INC. | $175.62 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $164.41 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $164.37 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $139.69 | 2024-2025 | Auvelity |
| Lundbeck LLC | $110.21 | 2025 | Rexulti |
| Indivior INC. | $101.42 | 2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $95.04 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $55.11 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $54.86 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $50.83 | 2025 | Nuplazid |
| Tempus Ai, INC | $36.28 | 2025 | Tempus Pixel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.53 | 2025 | Caplyta |
| Luye Pharma (USA) LTD. | $24.33 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $14.61 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.